Biotech catalyst, news and analysis PDUFA tracker
Outlook Therapeutics Inc
From the $0.23 post-CRL low to an FDA Formal Dispute Resolution victory — a narrative deep dive into how OTLK collapsed, survived, and what comes next with the LYTENAVA US BLA and the expected late July / early August 2026 FDA decision window.
Outlook Therapeutics remains one of the market’s purest high-risk ophthalmology regulatory stories. The company has a real product with European and UK authorization, but in the U.S. it is still stuck in a brutal loop: one 2023 CRL tied to manufacturing deficiencies, then two more CRLs in 2025 focused on insufficient evidence of effectiveness for wet AMD. That is the core problem the equity has been trading around for months.
After three Complete Response Letters and a long fight over what counts as sufficient evidence for ONS-5010 / LYTENAVA in wet AMD, Outlook Therapeutics has now moved into a formal FDA dispute-resolution process. This article walks through the CRL history, the new April 2026 meeting, and the real powers of the FDA deciding official — without hype, but also without pretending the door is already shut.
Outlook Therapeutics has become a fault line: some investors see a possible turnaround built on LYTENAVA’s European rollout and an FDA dialogue still technically open, others see only years of CRLs, value destruction and structural dilution risk. To really understand the stock you have to hold both sides of the story at the same time.
A post-CRL, post-Type A meeting request deep dive on ONS-5010/LYTENAVA, EU/UK launch reality, funding pressure and how much option value is left in a sub-$35M market cap.
Instead of a sterile list of dates, this piece focuses on context: how Corcept Therapeutics (CORT), Vanda Pharmaceuticals (VNDA) and Outlook Therapeutics (OTLK) are approaching their regulatory events, what their cash situation looks like, what the retail chatter is, and what kind of narrative one can realistically expect in a positive or negative outcome.
The FDA has accepted a new BLA resubmission for ONS-5010 and set a Class 1 PDUFA goal date on 31 December 2025, after a second CRL in August that focused on lack of substantial evidence of efficacy.
Binary Event Analysis: Outlook Therapeutics (OLTK) faces a critical PDUFA decision on December 31, 2025, for ONS-5010 (LYTENAVAâ„¢), a bevacizumab biosimilar for wet age-related macular degeneration (wet AMD).
